Lefferdink, Rachel
Rangel, Stephanie M. http://orcid.org/0000-0002-1206-9561
Chima, Margot
Ibler, Erin
Pavel, Ana B.
Kim, HeeJin
Wu, Benedict
Abu-Zayed, Hajar
Wu, Jianni
Jackson, Kathryn
Singer, Giselle
Choate, Keith A.
Guttman-Yassky, Emma
Paller, Amy S.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Secukinumab responses vary across the spectrum of congenital ichthyosis in adults
https://doi.org/10.1007/s00403-022-02325-3
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (SP0036673)
Article History
Received: 8 September 2021
Revised: 17 January 2022
Accepted: 20 January 2022
First Online: 26 February 2022
Declarations
:
: Drs. Lefferdink, Chima, Ibler, Pavel, Kim, Wu, and Rangel, and Ms. Abu-Zayed, Wu, Jackson, and Singer declare no conflicts. Dr. Choate has been an investigator for Alderya, Mayne, Galderma, and Regeneron and consultant with honorarium for AbbVie, Eli Lilly, Janssen, KrystalBio, Lifemax, Mayne, and Timber. Dr. Guttman-Yassky has been a researcher/consultant for AbbVie, Anacor, AnaptysBio, Asana Biosciences, Botanix, Celgene, DBV, Dermira, DS Biopharma, Escalier, Galderma, Glenmark, Innovaderm, Janssen, Kyowa Kirin, Leo Pharma, Lilly, MedImmune/AstraZeneca, Mitsubishi Tanabe, Novan, Novartis, Pfizer, Promius, Ralexar, Regeneron, Sanofi-Aventis, Stiefel/GlaxoSmithKline (GSK), UCB, and Vitae. Dr. Paller has been an investigator for AbbVie, AnaptysBio, Eli Lilly, Incyte, Janssen, KrystalBio, Novartis, Regeneron, and UCB and a consultant with honorarium for Abbvie, Abeona, Alcimed, Almirall, Amagma, Anaptysbio, Arena, Azitra, BiomX, Boehringer Ingelheim, Castle Biosciences, Catawba, Dermira, Eli Lilly, Exicure, Forte, Kamari, Leo, Lifemax, NAOS, Novartis, Pfizer, Phoenix, Pierre Fabre, Regeneron, Sanofi/Genzyme, Seanergy, Trifecta, and UCB. She has served on Data Safety Monitoring Boards for AbbVie, Bausch, Galderma, and Novan.
: This study was reviewed and approved by the institutional review boards of Northwestern University and Icahn School of Medicine at Mount Sinai Medical Center. IRB #: STU00202656/STU00202022 (NU); 17–00126 (MS).
: Informed consent was obtained from all individual participants included in the study.